Pertussis Infection in Adolescents and Adults With Prolonged Cough

Serological evidence of pertussis infection was defined as anti-pertussis toxin (PT) immunoglobulin G (IgG) level indicative of active or recent infection. The parameters presented were defined as follows: Seropositive = Subjects with anti-PT IgG ELISA levels ≥10 IU/ml , Seronegative = Subjects with anti-PT IgG ELISA levels \< 10 IU/ml , Sero-confirmed infection = Subjects with anti-PT IgG ELISA levels ≥62.5 IU/ml , Active infection 1= Anti-PT IgG ELISA levels ≥ 100 IU/ml indicative of active or recent infection, Active infection 2 = Anti-PT IgG ELISA levels ≥ 125 IU/ml indicative of active or recent infection

Time frame: At time of blood sampling (Day 0)

Population: The analysis was done on the According-to-Protocol (ATP) cohort which included all subjects with valid laboratory results.

Absenteeism was assessed as the mean number of days missed from work due to cough.

Time frame: At time of questionnaire administration (Day 0)

Population: The assessment was performed only on the subjects with sero-confirmed infection, i.e with Immunoglobulin G ELISA levels ≥ 62.5 IU/ml, and with available data.

Loss of income due to missing work for sero-confirmed subjects was measured in the local currency of each country, as follows: Malaysia - Malaysian ringgit (RM), Taiwan - New Taiwan dollar (NTD), Thailand - Thai baht (BAHT).

Time frame: At time of questionnaire administration (Day 0)

Population: The assessment was performed only on the subjects with sero-confirmed infection, i.e with Immunoglobulin G ELISA levels ≥62.5 IU/ml, and with available data.

Healthcare resource utilization was assessed by the mean number of visits to any type of physicians.

Time frame: At time of questionnaire administration (Day 0)

Population: The assessment was performed only on the subjects with sero-confirmed infection, i.e with Immunoglobulin G ELISA levels ≥62.5 IU/ml, and with available data.

The medical costs were assessed in the local currency of each country, as follows: Malaysia - Malaysian ringgit (RM). Total medical cost included the cost spent for consultation, medicines, laboratory tests etc., for visiting the emergency rooms.

Time frame: At time of questionnaire administration (Day 0)

Population: The assessment was performed only on the Malaysian subjects with sero-confirmed infection, i.e with Immunoglobulin G ELISA levels ≥62.5 IU/ml, and with available data.

The medical costs were assessed in the local currency of each country, as follows: Taiwan - New Taiwan dollar (NTD). Total medical cost included the cost spent for consultation, medicines, laboratory tests etc., for visiting the emergency rooms.

Time frame: At time of questionnaire administration (Day 0)

Population: The assessment was performed only on the Taiwanese subjects with sero-confirmed infection, i.e with Immunoglobulin G ELISA levels ≥62.5 IU/ml, and with available data.

The medical costs were assessed in the local currency of each country, as follows: Thailand - Thai baht (BAHT). Total medical cost included the cost spent for consultation, medicines, laboratory tests etc., for visiting the emergency rooms.

Time frame: At time of questionnaire administration (Day 0)

Population: The assessment was performed only on the Thailandese subjects with sero-confirmed infection, i.e with Immunoglobulin G ELISA levels ≥62.5 IU/ml, and with available data.

The medical costs were assessed in the local currency of each country, as follows: Malaysia - Malaysian ringgit (RM). Total medical cost included the cost spent for consultation, medicines, laboratory tests etc., for visiting the healthcare resources in general

Time frame: At time of questionnaire administration (Day 0)

Population: The assessment was performed only on the Malaysian subjects with sero-confirmed infection, i.e with Immunoglobulin G ELISA levels ≥62.5 IU/ml, and with available data.~One subject who reported 'out of pocket expenses' did not report 'Total medical cost'.

The medical costs were assessed in the local currency of each country, as follows: Taiwan - New Taiwan dollar (NTD). Total medical cost included the cost spent for consultation, medicines, laboratory tests etc., for visiting the healthcare resources in general

Time frame: At time of questionnaire administration (Day 0)

Population: The assessment was performed only on the Taiwanese subjects with sero-confirmed infection, i.e with Immunoglobulin G ELISA levels ≥62.5 IU/ml, and with available data.

The medical costs were assessed in the local currency of each country, as follows: Thailand - Thai baht (BAHT). Total medical cost included the cost spent for consultation, medicines, laboratory tests etc., for visiting the healthcare resources in general

Time frame: At time of questionnaire administration (Day 0)

Population: The assessment was performed only on the Thailandese subjects with sero-confirmed infection, i.e with Immunoglobulin G ELISA levels ≥62.5 IU/ml, and with available data.

The medical costs were assessed in the local currency of each country, as follows: Malaysia - Malaysian ringgit (RM). Total medical cost included the cost spent for consultation, medicines, laboratory tests etc., for visiting the specialist clinics.

Time frame: At time of questionnaire administration (Day 0)

Population: The assessment was performed only on the Malaysian subjects with sero-confirmed infection, i.e with Immunoglobulin G ELISA levels ≥62.5 IU/ml, and with available data.

The medical costs were assessed in the local currency of each country, as follows: Taiwan - New Taiwan dollar (NTD). Total medical cost included the cost spent for consultation, medicines, laboratory tests etc., for visiting the specialist clinics.

Time frame: At time of questionnaire administration (Day 0)

Population: The assessment was performed only on the Taiwanese subjects with sero-confirmed infection, i.e with Immunoglobulin G ELISA levels ≥62.5 IU/ml, and with available data.

The medical costs were assessed in the local currency of each country, as follows: Thailand - Thai baht (BAHT). Total medical cost included the cost spent for consultation, medicines, laboratory tests etc., for visiting the specialist clinics.

Time frame: At time of questionnaire administration (Day 0)

Population: The assessment was performed only on the Thailandese subjects with sero-confirmed infection, i.e with Immunoglobulin G ELISA levels ≥62.5 IU/ml, and with available data.

The medical costs were assessed in the local currency of each country, as follows: Malaysia - Malaysian ringgit (RM). Total medical cost included the cost spent for consultation, medicines, laboratory tests etc., for visiting the GP(s).

Time frame: At time of questionnaire administration (Day 0)

Population: The assessment was performed only on the Malaysian subjects with sero-confirmed infection, i.e with Immunoglobulin G ELISA levels ≥62.5 IU/ml, and with available data.~One subject who reported 'out of pocket expenses' did not report 'Total medical cost'.

The medical costs were assessed in the local currency of each country, as follows: Taiwan - New Taiwan dollar (NTD). Total medical cost included the cost spent for consultation, medicines, laboratory tests etc., for visiting the GP(s).

Time frame: At time of questionnaire administration (Day 0)

Population: The assessment was performed only on the Taiwanese subjects with sero-confirmed infection, i.e with Immunoglobulin G ELISA levels ≥62.5 IU/ml, and with available data.

The medical costs were assessed in the local currency of each country, as follows: Thailand - Thai baht (BAHT). Total medical cost included the cost spent for consultation, medicines, laboratory tests etc., for visiting the GP(s).

Time frame: At time of questionnaire administration (Day 0)

Population: The assessment was performed only on the Thailandese subjects with sero-confirmed infection, i.e with Immunoglobulin G ELISA levels ≥62.5 IU/ml, and with available data.

Total amount of time spent on seeing the doctor(s) which includes the return trip and the overall time spent at clinic(s)/hospital(s) for waiting, consultation, tests, pharmacy etc.

Time frame: At time of questionnaire administration (Day 0)

Population: The assessment was performed only on the subjects with sero-confirmed infection, i.e with Immunoglobulin G ELISA levels ≥62.5 IU/ml, and with available data.

The travel costs were assessed in the local currency of each country, as follows: Malaysia - Malaysian ringgit (RM).

Time frame: At time of questionnaire administration (Day 0)

Population: The assessment was performed only on the Malaysian subjects with sero-confirmed infection, i.e with Immunoglobulin G ELISA levels ≥62.5 IU/ml, and with available data.

The travel costs were assessed in the local currency of each country, as follows: Taiwan - New Taiwan dollar (NTD)

Time frame: At time of questionnaire administration (Day 0)

Population: The assessment was performed only on the Taiwanese subjects with sero-confirmed infection, i.e with Immunoglobulin G ELISA levels ≥62.5 IU/ml, and with available data.

The travel costs were assessed in the local currency of each country, as follows: Thailand - Thai baht (BAHT).

Time frame: At time of questionnaire administration (Day 0)

Population: The assessment was performed only on the Tailandese subjects with sero-confirmed infection, i.e with Immunoglobulin G ELISA levels ≥62.5 IU/ml, and with available data.

Health-related quality of life of pertussis patients was assessed using the EQ-5D Questionnaire. The EQ-5D is composed of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), with 3 levels of severity within each dimension. Average of EQ-5D index score (ranging from 0 to 1; 0 being death and 1 being in perfect health) across sero-confirmed participants was reported.

Time frame: At time of questionnaire administration (Day 0)

Population: The assessment was performed only on the subjects with sero-confirmed infection, i.e with Immunoglobulin G ELISA levels ≥62.5 IU/ml, and with available data.

Health-related quality of life of pertussis patients was assessed using the EQ-5D Questionnaire. The EQ-5D is composed of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), with 3 levels of severity within each dimension. The EQ-5D levels were further dichotomised into no problems (level 1) and with problems (level 2 & 3). The number of participants within these 2 levels are reported.

Time frame: At time of questionnaire administration (Day 0)

Population: The assessment was performed only on the subjects with sero-confirmed infection, i.e with Immunoglobulin G ELISA levels ≥62.5 IU/ml, and with available data.

Clinical features assessed included paroxysm, whoop, night cough, cyanosis, fever post-tussive vomiting, apnoea, cyanosis, coughing up phlegm, sneezes, wheezes, episodes of being unable to stop coughing and breathlessness/chest pain.

Time frame: At time of clinical data collection prior to enrolment (Day 0)

Population: The analysis was done on the ATP cohort for immunogenicity which included all subjects with valid laboratory results. For this outcome the subjects were grouped by their infection status: Subjects with Sero-confirmed infection and Subjects with Non-sero-confirmed infection.